Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (отвара нови прозор)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Извор‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Индекс‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (отвара нови прозор)

High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution. (отвара нови прозор)

Azzarà A, Carulli G, Galimberti S, Baratè C, Fazzi R, Cervetti G, Petrini M.

Извор‎: Am J Hematol 2011;86(9):762-7.

Индекс‎: PubMed 21850658

DOI‎: 10.1002/ajh.22111

https://www.ncbi.nlm.nih.gov/pubmed/21850658 (отвара нови прозор)

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (отвара нови прозор)

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

Извор‎: Acta Haematol 2007;117(3):162-7.

Индекс‎: PubMed 17148935

DOI‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 (отвара нови прозор)

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (отвара нови прозор)

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Извор‎: Am J Hematol 2013;88(12):990-6.

Индекс‎: PubMed 23873823

DOI‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 (отвара нови прозор)

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (отвара нови прозор)

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

Извор‎: J Clin Oncol 2011;29(28):3791-7.

Индекс‎: PubMed 21860000

DOI‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 (отвара нови прозор)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (отвара нови прозор)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Извор‎: Cancer 2012;118(3):848-55.

Индекс‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (отвара нови прозор)

Management of anemia in cancer patients. (отвара нови прозор)

Calabrich A, Katz A.

Извор‎: Future Oncol 2011;7(4):507-17.

Индекс‎: PubMed 21463140

DOI‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 (отвара нови прозор)

Leczenie ostrej białaczki u Świadków Jehowy—opis przypadku i przegląd piśmiennictwa. [Treatment of acute leukemia in Jehovah's Witnesses—a case report and review of the literature.] [Polish, English abstract] (отвара нови прозор)

Chojnowski K, Trelinski J.

Извор‎: Acta Haematol Pol 2007;38(4):479-84.

Индекс‎: EMBASE 2008089811

https://web.archive.org/web/20210506152723/https:/pthit.pl/Acta_Haematologica_Polonica,Ostra_bialaczka_Chemioterapia_Swiadkowie_Jehowy_Przetoczenie_krwi,395.html (отвара нови прозор)

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (отвара нови прозор)

Deger M, Eisterer W, Kutikova L, Salek S.

Извор‎: Support Care Cancer 2013;21(2):485-93.

Индекс‎: PubMed 22825456

DOI‎: 10.1007/s00520-012-1538-0

https://www.ncbi.nlm.nih.gov/pubmed/22825456 (отвара нови прозор)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (отвара нови прозор)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Извор‎: BJU Int 2011;108(10):1582-7.

Индекс‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (отвара нови прозор)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (отвара нови прозор)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Извор‎: J Clin Oncol 2010;28(13):2239-45.

Индекс‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (отвара нови прозор)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (отвара нови прозор)

Ford PA, Grant SJ, Mick R, Keck G.

Извор‎: J Clin Oncol 2015;33(15):1674-9.

Индекс‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (отвара нови прозор)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (отвара нови прозор)

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Извор‎: Br J Cancer 2011;105(9):1267-72.

Индекс‎: PubMed 21959870

DOI‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 (отвара нови прозор)

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (отвара нови прозор)

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

Извор‎: J Intern Med 2017;281(3):284-99.

Индекс‎: PubMed 27926979

DOI‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 (отвара нови прозор)

How I treat cancer-associated anemia. (отвара нови прозор)

Gilreath JA, Rodgers GM

Извор‎: Blood 2020;136(7):801-13.

Индекс‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (отвара нови прозор)

Update on safety of ESAs in cancer-induced anemia. (отвара нови прозор)

Glaspy J.

Извор‎: J Natl Compr Canc Netw 2012;10(5):659-66.

Индекс‎: PubMed 22570294

https://www.ncbi.nlm.nih.gov/pubmed/22570294 (отвара нови прозор)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (отвара нови прозор)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Извор‎: Eur J Haematol. 2023 110(4):354-61.

Индекс‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (отвара нови прозор)

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. (отвара нови прозор)

Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K.

Извор‎: Int J Hematol 2015;102(4):401-12.

Индекс‎: PubMed 26323997

DOI‎: 10.1007/s12185-015-1862-5

https://www.ncbi.nlm.nih.gov/pubmed/26323997 (отвара нови прозор)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (отвара нови прозор)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Извор‎: Cancer 2013;119(1):107-14.

Индекс‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (отвара нови прозор)

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (отвара нови прозор)

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

Извор‎: J Natl Cancer Inst 2013;105(14):1018-26.

Индекс‎: PubMed 23860204

DOI‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 (отвара нови прозор)

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (отвара нови прозор)

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Извор‎: Cancer Sci 2013;104(4):481-5.

Индекс‎: PubMed 23331490

DOI‎: 10.1111/cas.12105

https://www.ncbi.nlm.nih.gov/pubmed/23331490 (отвара нови прозор)

Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. (отвара нови прозор)

Park S, Greenberg P, Yucel A, Farmer C, O'Neill F, De Oliveira Brandao C, Fenaux P

Извор‎: Br J Haematol 2019;184(2):134-60.

Индекс‎: PubMed 30549002

DOI‎: 10.1111/bjh.15707

https://www.ncbi.nlm.nih.gov/pubmed/30549002 (отвара нови прозор)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (отвара нови прозор)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Извор‎: Support Care Cancer 2012;20(1):159-65.

Индекс‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (отвара нови прозор)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (отвара нови прозор)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Извор‎: Leuk Lymphoma. 2019;60(9):2324-7.

Индекс‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (отвара нови прозор)

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (отвара нови прозор)

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

Извор‎: Oncologist 2010;15(9):935-43.

Индекс‎: PubMed 20798194

DOI‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 (отвара нови прозор)

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (отвара нови прозор)

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Извор‎: Lung Cancer 2012;76(3):478-85.

Индекс‎: PubMed 22277104

DOI‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 (отвара нови прозор)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (отвара нови прозор)

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Извор‎: Eur J Haematol 2016;97(1):33-8.

Индекс‎: PubMed 26341961

DOI‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 (отвара нови прозор)

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (отвара нови прозор)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Извор‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Индекс‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (отвара нови прозор)

Intravenous iron in oncology. (отвара нови прозор)

Auerbach M, Ballard H.

Извор‎: J Natl Compr Canc Netw 2008;6(6):585-92.

Индекс‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 (отвара нови прозор)

Intravenous iron supplementation for the treatment of chemotherapy-induced anemia: a systematic review and meta-analysis of randomized controlled trials. (отвара нови прозор)

Buchrits S, Itzhaki O, Avni T, Raanani P, Gafter-Gvili A

Извор‎: J Clin Med. 2022;11(14):4156.

Индекс‎: PubMed 35887920

DOI‎: 10.3390/jcm11144156

https://pubmed.ncbi.nlm.nih.gov/35887920/ (отвара нови прозор)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (отвара нови прозор)

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

Извор‎: Int J Colorectal Dis 2016;31(3):543-51.

Индекс‎: PubMed 26694926

DOI‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 (отвара нови прозор)

How I treat cancer-associated anemia. (отвара нови прозор)

Gilreath JA, Rodgers GM

Извор‎: Blood 2020;136(7):801-13.

Индекс‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (отвара нови прозор)

Total dose iron dextran infusion in cancer patients: is it SaFe2+? (отвара нови прозор)

Gilreath JA, Stenehjem DD, Rodgers GM.

Извор‎: J Natl Compr Canc Netw 2012;10(5):669-76.

Индекс‎: PubMed 22570295

https://www.ncbi.nlm.nih.gov/pubmed/22570295 (отвара нови прозор)

Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. (отвара нови прозор)

Henry DH, Dahl NV, Auerbach MA.

Извор‎: Am J Hematol 2012;87(3):308-10.

Индекс‎: PubMed 22262486

DOI‎: 10.1002/ajh.22262

https://www.ncbi.nlm.nih.gov/pubmed/22262486 (отвара нови прозор)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (отвара нови прозор)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Извор‎: Eur J Haematol. 2023 110(4):354-61.

Индекс‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (отвара нови прозор)

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (отвара нови прозор)

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

Извор‎: Curr Oncol. 2023 24;30(9):7836-51.

Индекс‎: PubMed 37754484

DOI‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ (отвара нови прозор)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (отвара нови прозор)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Извор‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Индекс‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (отвара нови прозор)

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (отвара нови прозор)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

Извор‎: World J Gastroenterol 2014;20(8):1972-85.

Индекс‎: PubMed 24587673

DOI‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 (отвара нови прозор)

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (отвара нови прозор)

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

Извор‎: South Asian J Cancer. 2023 15;12(2):93-9.

Индекс‎: PubMed 37969669

DOI‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ (отвара нови прозор)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (отвара нови прозор)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Извор‎: J Clin Oncol 2008;26(10):1619-25.

Индекс‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (отвара нови прозор)

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (отвара нови прозор)

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

Извор‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

Индекс‎: PubMed 21972052

DOI‎: 10.1007/s00432-011-1072-3

https://www.ncbi.nlm.nih.gov/pubmed/21972052 (отвара нови прозор)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (отвара нови прозор)

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

Извор‎: Ann Oncol 2013;24(2):475-82.

Индекс‎: PubMed 23071262

DOI‎: 10.1093/annonc/mds338

https://www.ncbi.nlm.nih.gov/pubmed/23071262 (отвара нови прозор)

Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions. (отвара нови прозор)

Van Doren L, Steinheiser M, Boykin K, Taylor KJ, Menendez M, Auerbach M

Извор‎: Am J Hematol 2024;99(7):1338-48.

Индекс‎: PubMed 38282557

DOI‎: 10.1002/ajh.27220

https://pubmed.ncbi.nlm.nih.gov/38282557/ (отвара нови прозор)